Objective: To investigate the efficacy of a population health management initiative aimed at reducing the unnecessary use of proton pump inhibitors (PPIs) in elderly patients via a tapering process by measuring 1) the percentage of patients that initiate the PPI taper, 2) the number of patients 65 years of age and older with undocumented or unknown indication on PPI therapy for longer than eight weeks, and 3) the percentage of pharmacists' discontinuation recommendations accepted by the provider.
Design: Prospective, interventional pilot study.
Setting: Tier 3 patient-centered medical home within a major academic medical center with multiple sites.
Participants: Five hundred fifteen elderly patients were identified with an active PPI prescription for longer than eight weeks.
Interventions: A report was generated using the electronic health record to identify patients 65 years of age and older on PPI therapy. Patients were contacted via secure portal or telephone and provided with the risks and benefits by use of an educational online tool from RxFiles. Patients who were agreeable to begin a taper were provided an individualized plan. PPI use was monitored at a predesignated interval.
Main Outcome Measures: Patients initiating PPI taper, documented indication for PPI, and percent pharmacist recommendations accepted.
Results: Two hundred thirty-eight (46%) were eligible for intervention; 53 of 238 didn't have a documented indication. The provider approval rate of the pharmacist-recommended intervention was 86%, and 103 patients initiated the taper. Of these, 84 (81.6%) were successfully weaned off their PPI.
Conclusion: A systematic approach to deprescribing PPI therapy was successfully implemented for an elderly patient population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4140/TCP.n.2019.47 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification and dissection of prostate cancer grounded on fatty acid metabolism-correlative features for predicting prognosis and assisting immunotherapy.
Comput Biol Chem
December 2024
Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, China. Electronic address:
Background: Fatty acid metabolism (FAM) plays a critical role in tumor progression and therapeutic resistance by enhancing lipid biosynthesis, storage, and catabolism. Dysregulated FAM is a hallmark of prostate cancer (PCa), enabling cancer cells to adapt to extracellular signals and metabolic changes, with the tumor microenvironment (TME) playing a key role. However, the prognostic significance of FAM in PCa remains unexplored.
View Article and Find Full Text PDFIntroduction: Pembrolizumab stands as a first-line option for patients with advanced non-small cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression (PD-L1 ≥50%). Several factors such as antibiotic exposure, low body mass index (BMI), certain metastatic location or poor performance status may influence outcomes.
Methods: We conducted a multicenter retrospective analysis in a cohort of patients with advanced high PD-L1 expression NSCLC treated with first-line pembrolizumab in clinical practice.
VNS paired with training enhances recognition memory: mechanistic insights from proteomic analysis of the hippocampal synapse.
Front Mol Neurosci
December 2024
Cognitive Neuroscience, 711th Human Performance Wing, Air Force Research Laboratory, Wright-Patterson AFB, OH, United States.
Introduction: Recognition memory, an essential component of cognitive health, can suffer from biological limitations of stress, aging, or neurodegenerative disease. Vagus nerve stimulation (VNS) is a neuromodulation therapy with the potential to improve cognitive function. This study investigated the effectiveness of multiple sessions of VNS to enhance recognition memory in healthy rodents and the underlying cognitive benefits of VNS by proteomic analysis of the synaptosome.
View Article and Find Full Text PDFModulation of Pain Sensitivity by Ascl1- and Lhx6-Dependent GABAergic Neuronal Function in Streptozotocin-Diabetic Mice.
Mol Ther
December 2024
Gachon Pain Center and Department of Physiology, Gachon University College of Medicine, Incheon, Republic of Korea. Electronic address:
Painful diabetic neuropathy commonly affects the peripheral nervous system in individuals with diabetes. However, the pathological processes and mechanisms underlying diabetic neuropathic pain remain unclear. We aimed to identify the overall profiles and screen for genes potentially involved in pain mechanisms using transcriptome analysis of the dorsal root ganglion of diabetic mice treated with streptozotocin (STZ).
View Article and Find Full Text PDFNetwork pharmacology, molecular docking, and experimental verification to reveal the mechanism of colquhounia root tablet in the treatment of diabetic nephropathy.
Biochem Biophys Res Commun
December 2024
Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. Electronic address:
Article Synopsis
- Diabetic nephropathy (DN) is a common complication of diabetes, and Colquhounia Root Tablet (CRT) has shown potential therapeutic effects, although its mechanisms are not fully understood.
- Using various databases, researchers identified 163 therapeutic targets of CRT related to DN and found key targets like STAT3 and IL6 through protein-protein interaction analysis.
- The study highlighted the AGEs/RAGE signaling pathway as significant for CRT's effectiveness against DN and confirmed its protective effects on kidney cells via experimental treatments, although further studies are required to assess the safety and efficacy in real-life scenarios.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!